GlassScriptPhysician profile
Yanchun Zhang
NPI 1841363520
$35,051.38
in general payments reported to CMS, 2019-2025
9 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.81 · 2021: $22K · 2022: $8,228 · 2023: $4,758 · 2024: $16.62 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,375 · Travel and Lodging: $762 · Food and Beverage: $712 · Education: $34.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,375.00 |
| Travel and Lodging | $762.30 |
| Food and Beverage | $712.30 |
| Education | $34.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21,873.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $8,216.21 | 2022 | |
| Sk Life Science, INC. | $4,516.08 | 2023 | Xcopri |
| Abbvie INC. | $314.67 | 2022-2025 | Qulipta, Ubrelvy |
| Biogen, INC. | $41.81 | 2020 | |
| Alexion Pharmaceuticals, INC. | $34.12 | 2023 | Ultomiris |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Argenx US, INC. | $16.62 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $14.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanchun Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.